Clinical Trial Update: Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Atu027 in combination with gemcitabine for advanced or metastatic pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Atu027
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Silence Therapeutics GmbH | Conditions: Carcinoma, Pancreatic Ductal | Phase 1, Phase 2 | Status: COMPLETED